Opto-CRAC version 1 Citations (1)

Originally described in: Near-infrared photoactivatable control of Ca(2+) signaling and optogenetic immunomodulation.
He L, Zhang Y, Ma G, Tan P, Li Z, Zang S, Wu X, Jing J, Fang S, Zhou L, Wang Y, Huang Y, Hogan PG, Han G, Zhou Y Elife. 2015 Dec 8;4. pii: e10024. doi: 10.7554/eLife.10024. PubMed Journal

---

Articles Citing Opto-CRAC version 1

Articles
Identification of pimavanserin tartrate as a potent Ca(2+)-calcineurin-NFAT pathway inhibitor for glioblastoma therapy. Liu ZZ, Liu XN, Fan RC, Jia YP, Zhang QK, Gao XQ, Wang YQ, Yang MQ, Ji LZ, Zhou YQ, Li HL, Li P, Tang B. Acta Pharmacol Sin. 2021 Nov;42(11):1860-1874. doi: 10.1038/s41401-021-00724-2. Epub 2021 Aug 6. PubMed

If you have published an article using this material, please email us at to have your article added to this page.